Research Topics
Genomes and Genes | N K WengerSummaryAffiliation: Emory University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Menopausal hormone therapy: is there evidence for cardiac protection?Nanette K Wenger
Division of Cardiology, Emory University School of Medicine, USA
Int Urol Nephrol 36:617-23. 2004..The latter Guidelines display the lifestyle and pharmacologic interventions that are appropriate for cardiovascular disease risk reduction for women...
Gender disparity in cardiovascular disease: bias or biology?Nanette K Wenger
Department of Medicine Cardiology, Emory University School of Medicine, Consultant, Emory Heart and Vascular Center, Atlanta, GA, USA
Expert Rev Cardiovasc Ther 10:1401-11. 2012....- What's New in Antiplatelet and Anticoagulant Therapy Recommendations for Unstable Angina/Non-ST-Elevation Myocardial Infarction: 2012 Focused Update From the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuideNanette K Wenger
Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia
Clin Cardiol 35:669-72. 2012..The author has no funding, financial relationships, or conflicts of interest to disclose... 
Strategies and methods to study sex differences in cardiovascular structure and function: a guide for basic scientistsVirginia M Miller
Departments of Surgery, Physiology and Biomedical Engineering, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA
Biol Sex Differ 2:14. 2011..abstract:..- Cardiovascular disease: the female heart is vulnerable: a call to action from the 10Q reportNanette K Wenger
Department of Medicine Cardiology, Emory University School of Medicine, Atlanta, Georgia
Clin Cardiol 35:134-5. 2012.... - Coronary heart disease in women: update 2008N K Wenger
Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
Clin Pharmacol Ther 83:37-51. 2008..Although these women have more comorbidity and risk factors, other issues including biological differences, treatment differences, and psychosocial factors require management strategies tailored to the unique needs of women... - HT and CVD prevention. from myth to realityNanette K Wenger
Emory University School of Medicine, Atlanta, GA 30303, USA
Fertil Steril 80:10-4; quiz 54-5. 2003..Coronary prevention should involve lifestyle and pharmacologic interventions documented as beneficial in randomized clinical trials and promulgated in national guidelines... - Enrollment and maintenance of elderly patients in cardiovascular clinical trialsNanette K Wenger
Division of Cardiology, Department of Medicine, Emory University School of Medicine, 49 Jessie Hill Jr Drive SE, Atlanta, GA 30303, USA
Am J Geriatr Cardiol 15:352-6. 2006..Relevant clinical outcomes include improvement in functional independence and quality of life, decrease in costly hospitalizations, and prolongation of meaningful life... - Current status of cardiac rehabilitationNanette K Wenger
Emory University School of Medicine, Atlanta, Georgia 30303, USA
J Am Coll Cardiol 51:1619-31. 2008..The core components of cardiac rehabilitation have been delineated in detail. Implementation of newly available performance measures offers the potential to enhance referral to, enrollment in, and completion of cardiac rehabilitation... - [Menopausal hormone therapy and cardiovascular disease]Nanette K Wenger
Emory University School of Medicine, Grady Memorial Hospital, Emory Heart and Vascular Center, Atlanta, Georgia, USA
Rev Esp Cardiol 59:1058-69. 2006.... - Coronary heart disease: the female heart is vulnerableNanette K Wenger
Emory School of Medicine and Grady Memorial Hospital, Emory Heart and Vascular Center, Atlanta, GA 30303, USA
Prog Cardiovasc Dis 46:199-229. 2003..Research indicates that behavioral changes on the part of women and reshaping of practice patterns by their health care providers may dramatically reduce the number of women disabled and killed by CHD each year... - Drugs for cardiovascular disease prevention in women: implications of the AHA Guidelines--2007 UpdateNanette K Wenger
Emory University School of Medicine, Atlanta, Georgia, USAGrady Memorial Hospital, Atlanta, Georgia, USAEmory Heart and Vascular Center, Atlanta, Georgia 30303, USA
Drugs 68:339-58. 2008..This information gap presents a major challenge for future studies, as these subgroups constitute populations of women at high cardiovascular risk... - Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart diseaseNanette K Wenger
Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia 30303, USA
Ann Intern Med 147:1-9. 2007..Increased life expectancy is associated with an increase in the burden of chronic cardiovascular disease... - Dyslipidemia as a risk factor at elderly ageNanette K Wenger
Emory University School of Medicine, Atlanta, GA 30303, USA
Am J Geriatr Cardiol 13:4-9. 2004..About one third of elderly men and one half of elderly women have cholesterol levels >240 mg/dL. Remediable dyslipidemia is highly relevant at elderly age and should guide recommendations for cardiovascular disease prevention... - Do diet, folic acid, and vitamins matter? What did we learn from the Women's Health Initiative, the Women's Health Study, the Women's Antioxidant and Folic Acid Cardiovascular Study, and other clinical trials?Nanette K Wenger
Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA 30303, USA
Cardiol Rev 15:288-90. 2007.... - You've come a long way, baby: cardiovascular health and disease in women: problems and prospectsNanette K Wenger
Division of Cardiology, Emory University School of Medicine, Grady Memorial Hospital, and Emory Heart and Vascular Center, Atlanta, GA 30303, USA
Circulation 109:558-60. 2004 - Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) studyN K Wenger
Emory University School of Medicine, 49 Jesse Hill Jr Drive, SE Atlanta, GA 30303, USA
Heart 94:434-9. 2008..To examine by secondary analysis of the Treating to New Targets (TNT) study whether the benefits of intensive versus standard levels of lipid lowering are equally applicable to women... - Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trialsNanette K Wenger
Department of Medicine, Emory University School of Medicine, Grady Memorial Hospital, Atlanta, GA, USA
Am J Cardiol 99:11-8. 2007.... - Lipid abnormalities in women: data for risk, data for managementNanette K Wenger
Department of Medicine Cardiology, Emory University School of Medicine, The Department of Cardiology, Grady Memorial Hospital, and the Emory Heart and Vascular Center, Atlanta, Georgia 30303, USA
Cardiol Rev 14:276-80. 2006..Application of lipid-lowering therapy with statin drugs is currently underutilized in women, and represents an opportunity to improve clinical cardiovascular outcomes for women... - Menopausal hormone therapy: currently no evidence for cardiac protectionNanette K Wenger
Division of Cardiology, Emory University School of Medicine Grady Memorial Hospital Emory Heart and Vascular Center, Atlanta, Georgia, USA
Pediatr Blood Cancer 44:625-9. 2005.... - Angina in womenNanette K Wenger
Emory University School of Medicine, 49 Jesse Hill Jr Drive, SE, Atlanta, GA 30303, USA
Curr Cardiol Rep 12:307-14. 2010..Women also have more non-chest pain manifestations of myocardial ischemia than men. These variables must be incorporated in assessments of optimal diagnostic and therapeutic strategies for myocardial ischemia in women... - Lipid metabolism, physical activity, and postmenopausal hormone therapyN K Wenger
Department of Medicine, Emory University School of Medicine, and Grady Memorial Hospital, Atlanta, GA 30303, USA
Am J Kidney Dis 32:S80-8. 1998..Goals for coronary risk factor intervention must be developed for patients with specific subsets of chronic renal disease... - Coronary heart disease in women: highlights of the past 2 years--stepping stones, milestones and obstructing bouldersNanette K Wenger
Division of Cardiology, Emory University School of Medicine, Atlanta, GA 30303, USA
Nat Clin Pract Cardiovasc Med 3:194-202. 2006..Adherence to recommendations offers the promise of improving the heart health of women. In this article, I summarize new information to guide the preventive, diagnostic and therapeutic management of CHD in women... - Cardiovascular effects of raloxifene: the potential for cardiovascular protection in womenN K Wenger
Emory University School of Medicine, Grady Memorial Hospital, Emory Heart and Vascular Center, Atlanta, GA 30303, USA
Diabetes Obes Metab 4:166-76. 2002 - Managing ambulatory anticoagulationN K Wenger
Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia 30303, USA
J Thromb Thrombolysis 12:31-4. 2001.... - Coronary revascularization in womenNanette K Wenger
Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia 30303, USA
Cardiol Rev 13:184-9. 2005..Procedural bleeding complications, among others, warrant pathophysiologic assessment; limitation of such complications can improve clinical outcomes for women... - 2011 ACCF/AHA focused update of the guidelines for the management of patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 Guideline): highlights for the clinicianNanette K Wenger
Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia, USA
Clin Cardiol 35:3-8. 2012.... - What do the 2011 American Heart Association guidelines tell us about prevention of cardiovascular disease in women?Nanette K Wenger
Emory University School of Medicine, Emory Heart aned Vascular Center, Atlanta, Georgia 30322, USA
Clin Cardiol 34:520-3. 2011..Defining a woman's risk status and improving her adherence to preventive lifestyle behaviors and medications is the best strategy to lower the burden of CVD in women... - Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trialNanette Kass Wenger
Emory University, Atlanta, Georgia 30303, USA
Am J Cardiol 90:1204-10. 2002.... - Menopausal hormone therapy for cardiovascular protection--unfulfilled expectationsNanette K Wenger
Grady Memorial Hospital, Atlanta, GA, USA
J Cardiovasc Transl Res 2:286-8. 2009..Much remains unknown about the mechanisms of menopausal hormone therapy action and the issue of whether there is a therapeutic window of opportunity for its use... - The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the platelet GPIIIa gene with myocardial infarction and venous thromboembolism in African AmericansW C Hooper
Hematologic Disease Branch, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Center for Disease Control and Prevention, Atlanta, GA 30333, USA
Chest 116:880-6. 1999..Because these two genes may interact physiologically, the third objective was to determine if there was a relationship between the polymorphisms with respect to MI and VTE... - Cardiovascular disease prevention tailored for womenNiels Engberding
Division of Cardiology, Emory University, School of Medicine, Atlanta, GA 30303, USA
Expert Rev Cardiovasc Ther 6:1123-34. 2008..Observational data continue to identify discrepancies between women and men, which target areas of need for future research... - Adherence to screening guidelines for breast and cervical cancer in postmenopausal women with coronary heart disease: an ancillary study of volunteers for hersP Z Castellano
Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia, USA
J Womens Health Gend Based Med 10:451-61. 2001..Provider behavior was an important factor in influencing women to obtain preventive screening. There were no significant differences in compliance based on provider gender or type of coronary event preceding HERS enrollment... - Hypertension and other cardiovascular risk factors in womenN K Wenger
Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
Am J Hypertens 8:94s-99s. 1995..Education is important; unless women consider CHD as part of their illness experience, they are unlikely to heed preventive messages... - Depressive symptoms after acute myocardial infarction: evidence for highest rates in younger womenSusmita Mallik
Department of Medicine, Division of General Medicine, Emory University School of Medicine, Atlanta, GA 30303, USA
Arch Intern Med 166:876-83. 2006..Because depression after AMI has been associated with adverse outcomes, younger women, a high-risk group compared with men, may particularly benefit from aggressive screening and treatment of post-AMI depression... - Menopausal hormone therapy and cardiovascular protection: state of the data 2003Nanette K Wenger
Emory University School of Medicine, Atlanta, Georgia, USA
J Am Med Womens Assoc 58:236-9. 2003.... - Comparison of angiographic findings among postmenopausal women using unopposed estrogen, estrogen/progestin combinations, and nonusersLiudmila Husak
Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia 30306, USA
Am J Cardiol 93:563-8. 2004..59 to 0.98). Thus, the apparent protective effect of combination menopausal hormone therapy with E+P on CAD is due to differences in other patient characteristics. In contrast, unopposed E therapy may have a protective effect on CAD... - Venous thrombosis in relation to fibrinogen and factor VII genes among African-AmericansH Austin
Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, U S Department of Health and Human Services, Atlanta, GA 30333, USA
J Clin Epidemiol 53:997-1001. 2000..The study also indicated that the HaeIII and the BclI polymorphisms of the beta fibrinogen gene and the MspI polymorphisms of the factor VII gene are not strong determinants of venous thrombosis... - Preventing cardiovascular disease in women: an updateNanette K Wenger
Emory University School of Medicine, Grady Memorial Hospital, Emory Heart and Vascular Center, Atlanta, Georgia, USA
Clin Cardiol 31:109-13. 2008..However, high coronary risk in many women continues to be underrecognized, and women remain undertreated with statins and other therapeutic agents... - Management strategies of dyslipidemia in the elderly: 2005Tarek Helmy
Grady Memorial Hospital, Atlanta, Georgia, USA
MedGenMed 7:8. 2005..Compelling data noted from recent clinical trials have prompted the NCEP to publish an updated report that addresses the significant interim developments... - Clinical characteristics of coronary heart disease in women: emphasis on gender differencesNanette K Wenger
Emory University School of Medicine, Division of Cardiology, Grady Memorial Hospital, 69 Butler Street, S.E, Atlanta, GA 30303, USA
Cardiovasc Res 53:558-67. 2002 - Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002Viola Vaccarino
Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA 30306, USA
N Engl J Med 353:671-82. 2005..Although increased attention has been paid to sex and racial differences in the management of myocardial infarction, it is unknown whether these differences have narrowed over time... - The Metabolic Syndrome in African Americans: a reviewW Dallas Hall
African American Lipid and Cardiovascular Council, USA
Ethn Dis 13:414-28. 2003..This comprehensive review is provided as part of the educational activities of the African-American Lipid and Cardiovascular Council (AALCC)... - Time course of depression and outcome of myocardial infarctionSusmita Parashar
Divisions of General Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30303, USA
Arch Intern Med 166:2035-43. 2006..Our objective was to evaluate the prognostic importance of transient, new, or persistent depression on outcomes at 6 months after MI... - Race, gender, and mortality in adults > or =65 years of age with incident heart failure (from the Cardiovascular Health Study)Susmita Parashar
Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
Am J Cardiol 103:1120-7. 2009..In conclusion, in older adults with HF, women had significantly better survival than men irrespective of race, suggesting that gender-based survival differences may be more important than race-based differences... - Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgerySanjiv J Shah
Division of Cardiology, San Francisco General Hospital, University of California, San Francisco, California 94110, USA
J Am Coll Cardiol 51:1938-43. 2008.... - Review of the treatment of acute coronary syndrome in elderly patientsMaan Jokhadar
Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA
Clin Interv Aging 4:435-44. 2009.... - Baseline characteristics of menopausal women with coronary heart disease in cardiovascular outcomes clinical trials of menopausal hormone therapy or raloxifeneNanette K Wenger
Emory University School of Medicine, Atlanta, GA 30303, USA
Contemp Clin Trials 26:612-5. 2005..More aggressive cardiovascular risk factor interventions are requisite to achieve optimal target goals for women with documented coronary heart disease... - Cardiovascular disease in the elderlyN K Wenger
Department of Medicine Division of Cardiology Emory University School of Medicine, Atlanta, Georgia
Curr Probl Cardiol 17:609-90. 1992..are indeed formative years, rich in possibilities to unlearn the follies of a lifetime, to see through inbred deceptions, to deepen understanding and compassion, to widen the horizon of honesty, to refine the sense of fairness... - Recognition and prevention of cardiovascular disease in womenKimberly P Champney
Emory University School of Medicine, Atlanta, GA, USA
Compr Ther 31:255-61. 2005..Initiation of menopausal hormone therapy is not recommended for the prevention of coronary heart disease or stroke in women... - Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trialsMardi Gomberg-Maitland
Department of Medicine, Section of Cardiology, University of Chicago Hospitals, University of Chicago, 5841 S Maryland Avenue, MC2016, Chicago, IL 60637, USA
Eur Heart J 27:1947-53. 2006..The risk of stroke is greater among women with atrial fibrillation (AF) than men. Warfarin protects against stroke, but treatment-related bleeding occurs more often in women than in men... - Relationship of venous thromboembolism and myocardial infarction with the renin-angiotensin system in African-AmericansW Craig Hooper
Hematological Disease Branch, Centers for Disease Control and Prevention, MS D02, 1600 Clifton Road, Atlanta, GA 30333, USA
Am J Hematol 70:1-8. 2002..The data also demonstrated that the allele frequencies of the A1166C variant of the angiotensin II type I receptor were different in African-Americans as compared to Caucasians... - Secondary prevention of coronary heart disease in elderly patientsIbrahim R Hanna
Emory University School of Medicine, Atlanta, Georgia 30303, USA
Am Fam Physician 71:2289-96. 2005..Strategies aimed at these factors have shown variable results and remain ill-defined... - Treating dyslipidemia in the elderlyKhan Pohlel
Emory University School of Medicine, Atlanta, Georgia 30303, USA
Curr Opin Lipidol 17:54-7. 2006..There is no known panacea for managing these chronic disease conditions; however, lipid-lowering therapy has been shown to prevent or delay the progression of these diseases and the mortality and morbidity that accompanies them... - Gender differences in short-term cardiovascular outcomes after percutaneous coronary interventionsEdgar Argulian
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
Am J Cardiol 98:48-53. 2006..No differences were found in major in-hospital complications by gender... - Prehypertension and cardiovascular disease risk in the Women's Health InitiativeJudith Hsia
Department of Medicine, George Washington University, 2150 Pennsylvania Ave NW, Washington, DC 20037, USA
Circulation 115:855-60. 2007..Prehypertension is common and is associated with increased vascular mortality. The extent to which it increases risk of nonfatal myocardial infarction, stroke, and congestive heart failure is less clear... - Coronary heart disease in women: battle is won, but the war remainsP K Mehta
Department of Cardiology, Emory University School of Medicine, Atlanta, GA 30303, USA
Minerva Med 98:459-78. 2007.... - Mutations in the genes regulating methylene tetrahydrofolate reductase (MTHFR C-->T677) and cystathione beta-synthase (CBS G-->A919, CBS T-->c833) are not associated with myocardial infarction in African AmericansA Dilley
Hematologic Diseases Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop E 64, Atlanta, GA 30333, USA
Thromb Res 103:109-15. 2001..No mutations for G-->A919 (CBS) were detected in the cases or controls. The racial differences of the CBS T-->C833 polymorphism suggest that further investigation into the other areas of the CBS gene is needed... - Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) studyKiran K Khush
Division of Cardiology, University of California, San Francisco School of Medicine, San Francisco, Calif, USA
Circulation 115:576-83. 2007..Statins reduce the rate of major cardiovascular events in high-risk patients, but their potential benefit as treatment for heart failure (HF) is less clear... - Coronary heart disease and women: magnitude of the problemNanette K Wenger
Emory University School of Medicine, Atlanta, Georgia, USA
Cardiol Rev 10:211-3. 2002 - The metabolic syndrome: recognition and managementW Dallas Hall
Emory University School of Medicine, Atlanta, GA, USA
Dis Manag 9:16-33. 2006..Pharmacotherapy is typically needed for control of high blood pressure, hypercoagulability, and increased levels of blood glucose and triglycerides... - Hippocrates, Maimonides, and End-of-Life IssuesNanette K Wenger
Emory University School of Medicine, Atlanta, GA 30303
Am J Geriatr Cardiol 13:291-2. 2004 - Guidelines of the Cardiogeriatrics Department of the Brazilian Cardiology Society: commentary by Editorial Board Members of The American Journal of Geriatric CardiologyNanette K Wenger
Emory University School of Medicine, Atlanta, GA 30303, USA
Am J Geriatr Cardiol 13:209-16. 2004 - Nanette K. Wenger: a woman's life in cardiologyJoseph S Alpert
Department of Medicine, University of Arizona Health Sciences Center, Tucson, USA
Clin Cardiol 27:114-5. 2004 - Chronic kidney disease and cognitive impairment in menopausal womenManjula Kurella
Department of Medicine, Divisions of Nephrology, University of California San Francisco, CA 94118-1211, USA
Am J Kidney Dis 45:66-76. 2005..CONCLUSION: CKD is associated with cognitive impairment in menopausal women with coronary artery disease... - Reflections of a "lady doctor"Nanette K Wenger
Division of Cardiology, Emory University School of Medicine, USA
J Med Assoc Ga 92:13-4. 2003 - Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > or =75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, aMark A Williams
Circulation 105:1735-43. 2002 - For the patient. What is the Metabolic Syndrome and why is it important?W Dallas Hall
Ethn Dis 13:546. 2003 - Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary riskDeborah Grady
University of California, San Francisco, and San Francisco VA Medical Center, San Francisco, CA 94115, USA
J Natl Cancer Inst 100:854-61. 2008..Here, we provide further details about breast cancer incidence by tumor characteristics, duration of treatment, and subgroup... - Drug therapy in the elderlyStephen Scheidt
Am J Geriatr Cardiol 12:223-4. 2003 - Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, PhysicalPaul D Thompson
Circulation 107:3109-16. 2003 - Review of the International Position Paper on Women's Health and Menopause: a comprehensive approachRodolfo Paoletti
Department of Pharmacological Sciences, University of Milan, Milan, Italy
Circulation 107:1336-9. 2003 - [The current state of hormonal prevention of coronary heart disease in menopausal women]Nanette K Wenger
Rev Esp Cardiol 56:1-8. 2003.... - Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) studyJames Shepherd
Department of Vascular Biochemistry, University of Glasgow, G31 2ER, UK
Clin J Am Soc Nephrol 2:1131-9. 2007..This subanalysis of the Treating to New Targets study investigated how intensive lipid lowering with 80 mg of atorvastatin affects renal function when compared with 10 mg in patients with coronary heart disease... - Atrial fibrillation: many therapeutic options, but great uncertainty about optimal treatmentStephen Scheidt
Am J Geriatr Cardiol 11:350-1. 2002 - Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learnedCurt D Furberg
Wake Forest University School of Medicine, Winston Salem, NC 27157 1063, USA
Circulation 105:917-22. 2002..We analyzed the HERS data to determine whether there were specific subgroups of women who responded differently to treatment, either during the first year or in the overall study... - Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) studyJames Shepherd
University of Glasgow, Glasgow, United Kingdom
J Am Coll Cardiol 51:1448-54. 2008..This subanalysis of the TNT (Treating to New Targets) study investigates the effects of intensive lipid lowering with atorvastatin in patients with coronary heart disease (CHD) with and without pre-existing chronic kidney disease (CKD)... - Sexual satisfaction and cardiovascular disease: the Women's Health InitiativeJennifer S McCall-Hosenfeld
VA Boston Healthcare System, Boston, MA, USA
Am J Med 121:295-301. 2008..We investigated whether dissatisfaction with sexual activity, a domain of female sexual dysfunction, is associated with prevalent and incident cardiovascular disease in postmenopausal women... - Intensive lipid lowering with atorvastatin in patients with stable coronary diseaseJohn C LaRosa
State University of New York Health Science Center, Brooklyn, NY 11203, USA
N Engl J Med 352:1425-35. 2005..This occurred with a greater incidence of elevated aminotransferase levels... - Who should be treated with implantable cardioverter-defibrillators?Michael A Weber
Am J Geriatr Cardiol 15:336-7. 2006 - Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: Consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, CounJennifer H Mieres
Circulation 111:682-96. 2005.... - Common cardiac conditions in the elderly are still not well understoodMichael A Weber
Am J Geriatr Cardiol 13:237-8. 2004 - Denial of standard treatment to the elderly: why?Stephen Scheidt
Am J Geriatr Cardiol 16:5-7. 2007 - Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical CardiologyPaul D Thompson
Hartford Hospital, USA
Circulation 115:2358-68. 2007.... - Diet and exercise for perimenopausal women lifestyle interventions can decrease cardiovascular riskNanette K Wenger
J Am Coll Cardiol 44:586-7. 2004 - Chronic kidney disease is a cardiovascular problem--implications for lipid managementNanette K Wenger
Am J Cardiol 94:167-8. 2004 - Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statementLori Mosca
Arterioscler Thromb Vasc Biol 24:e29-50. 2004 - Newer diagnostic strategies, application of evidence-based therapies: improving cardiovascular outcomes in an expanding elderly populationNanette K Wenger
Am J Geriatr Cardiol 16:337-8. 2007 - Evidence-based guidelines for cardiovascular disease prevention in womenLori Mosca
J Am Coll Cardiol 43:900-21. 2004 - Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?David D Waters
University of California, San Francisco School of Medicine, San Francisco, California 94110, USA
Am J Cardiol 93:154-8. 2004..9 mmol/L) can provide additional clinical benefit... - Creatinine levels and cardiovascular events in women with heart disease: do small changes matter?Michael G Shlipak
General Internal Medicine Section, Veterans Affairs Medical Center, San Francisco, CA 94121, USA
Am J Kidney Dis 43:37-44. 2004.... - Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal womenElizabeth Barrett-Connor
Department of Family and Preventive Medicine, University of California, San Diego, La Jolla 92093 0607, USA
N Engl J Med 355:125-37. 2006..The effect of raloxifene, a selective estrogen-receptor modulator, on coronary heart disease (CHD) and breast cancer is not established...